Angiogenesis in urological malignancy: prognostic indicator and therapeutic target.
Jones
A
A
Department of Urology, Churchill Hospital, Oxford, UK.
Fujiyama
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002450:Cell Communication; D005109:Extracellular Matrix / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D008833:Microcirculation; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D009857:Oncogenes / Q000502:physiology; D011379:Prognosis; D013939:Thymidine Phosphorylase / Q000378:metabolism; D014565:Urogenital Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D016222:Fibroblast Growth Factor 2; D013939:Thymidine Phosphorylase